✦ LIBER ✦

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma

✍ Scribed by Leo I Gordon; Thomas E Witzig; Greg A Wiseman; Ian W Flinn; Stewart S Spies; Daniel H Silverman; Christos Emmanuolides; Larry Cripe; Mansoor Saleh; Myron S Czuczman; Teresa Olejnik; Christine A White; Antonio J Grillo-López

Book ID: 114481150
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 84 KB
Volume: 29
Category: Article
ISSN: 0093-7754
DOI: 10.1053/sonc.2002.30148

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II90Y-Zevalin (yttrium-90 ibritu

Phase I/II90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma

✍ Gregory A. Wiseman; Christine A. White; Michael Stabin; William L. Dunn; William 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 166 KB

External beam radiation therapy after 90

External beam radiation therapy after 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory CD20+ non-Hodgkin’s lymphoma

✍ T.E Justice; J.A Martenson; G.A Wiseman; T.E Witzig 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Radioimmunotherapy in Non-Hodgkin's Lymp

Radioimmunotherapy in Non-Hodgkin's Lymphoma: Trials of Yttrium 90–Labeled Ibritumomab Tiuxetan and Beyond

✍ Evens, Andrew M.; Gordon, Leo I. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 129 KB

Weight-Based Dosing of Yttrium 90 Ibritu

Weight-Based Dosing of Yttrium 90 Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

✍ Wiseman, Gregory A.; Conti, Peter S.; Vo, Katie; Schilder, Russell J.; Gordon, L 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 106 KB

Efficacy and safety of 90Y ibritumomab t

Efficacy and safety of 90Y ibritumomab tiuxetan (zevalin) radioimmunotherapy for non-Hodgkin’s lymphoma

✍ Thomas E Witzig 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Long-term responses in patients with rec

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w